Currently, Romania is ranked first in Europe in terms of cervical cancer mortality. In this context, the solution which has been developed in recent years is the secondary use of molecular markers more specific for cervical precancer, combining their high sensitivity with high specificity. Among these methods, p16 / Ki67 dual immunocytochemistry is the most studied.
One hundred and eighty-three patients who performed the Papanicolaou test, the HPV-DNA test and the immunocytochemistry test (CINtec PLUS) from June 2014 to June 2017 were examined. Patients with the positive CINtec PLUS test were recommended for a colposcopy examination and subsequent biopsy.
The sensitivity and the negative predictive value of CINtec PLUS was 100%, the specificity 75,2% and the positive predictive value 60,2%. Performing a double staining test in patients with ASCUS type cervical cytology changes in the study group has been shown to be very effective in identifying precancerous cervical lesions.
Thus, by using the p16/ Ki-67 immunocytochemical staining, the medical attitude in screening or monitoring young patients with HPV infection, high-risk strain and ASC-US, the results being optimized. Unnecessary colposcopy examinations are avoided (indications of colposcopy are restricted to CINtec PLUS Positive and invasive gestures on nulliparous women are limited. CINtec PLUS negative results are monitored by repeating cytology testing and HPV DNA testing at 12 months.